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Introduction
Increasing interest is being focused on genetic factors that are known to modify pain sensitivity and analgesic responses. 37 An example is the 118A>G polymorphism (rs1799971) in the OPRM1 gene on chromosome 6 coding for the mu-opioid receptor. This polymorphism leads to asparagine being replaced by aspartate, which changes the N-glycosylation of the protein. 2, 13 The polymorphism is relatively common, having a frequency around 10-15% in the European populations, but there is also large interethnic variability in the allele frequency. 34 This amino acid change alters the binding potential and half-life of the receptor and thereby modulates the downstream functions of the receptor. 2, 6, 13 Also contradictory findings exist and it seems possible that the molecular consequences of this polymorphism are cell or tissue type specific. 34 As 118A>G has the highest allelic frequency of all amino acid altering OPRM1 SNPs and the mu-opioid receptor conveys most of the opioid effects this polymorphism could significantly influence the response to opioid therapy.
Opioids are the most commonly used analgesics for moderate to severe pain. 32 So far the impact of genetic variation of the mu-opioid receptor in analgesia has remained controversial. Several studies have associated the 118A>G polymorphism to increased opioid consumption and pain sensitivity 29, 31 while others have failed to find any evidence of association between this polymorphism and opioid effectiveness or adverse effects. 22 Many studies have had small sample sizes 40 or a low frequency of the G-allele.
A meta-analysis from 2009 concluded that the 118A>G polymorphism showed no overall association with opioid analgesia. 35 However, that meta-analysis did not include any studies on oxycodone. In another recent meta-analysis the polymorphism was shown to be reproducibly associated with decreased opioid effects but due to the small effect size the clinical relevance of this association was questioned. 34 Non-cancer related use of oxycodone, including intravenous administration, is increasing worldwide. 14, 25 The association between postoperative oxycodone consumption and the mu-opioid receptor polymorphism has been addressed before in only one small study which found no association between the OPRM1 1118A>G polymorphism and postoperative oxycodone analgesia. 40 The aim of our study was to assess the role of the OPRM1 118A>G polymorphism in postoperative oxycodone analgesia. Our study cohort consists of 1,000 wellcharacterized women undergoing surgery for breast cancer. A study sample of this size should enable estimation of the true effect size of this variant. We also used the amount of oxycodone needed for the first state of adequate analgesia as the primary outcome for oxycodone analgesia as other measures of opioid consumption are likely to be influenced more by pharmacokinetic factors. In addition, we studied the role of the OPRM1 118A>G polymorphism in experimental pain sensitivity using both heat and cold stimulation.
Methods

Ethics
The The study cohort has been described in more detail by Kaunisto and others. 18 
Study procedure
The research nurse collected patient characteristics the day before the surgery.
The background data included e.g. age, weight and height, number of previous operations (other than breast surgery) and previous chronic pain of any kind. 18 Patients also answered psychological questionnaires, Beck Depression Inventory 1 and Spielberger State and Trait Anxiety Inventory. 30 Pain in the chest/axillary area was assessed using a numerical rating scale (NRS 0-10).
Before surgery the research nurse tested the patients for heat and cold pain In the PACU the patients were asked to rate the pain intensity at rest and during movement using NRS 0-10. Motion pain was assessed by asking the patient to raise the arm ipsilateral to surgery up to 90˚. Analgesia was titrated by the research nurse who asked about the pain intensity every 5 minutes and administered 1-3 mg oxycodone until the patient rated the pain intensity <4 (NRS 0-10) or indicated otherwise that pain relief was adequate. Afterwards pain intensity was assessed every 15 min until the patient needed a new dose of oxycodone.
After two hours the patients were transferred to the ward and analgesia was 
Genotyping
DNA was extracted from peripheral blood using the Autopure LS automated DNA purification instrument (Gentra Systems, Inc., Minneapolis, MN, USA). OPRM1 118A>G (rs1799971) was genotyped using the Sequenom MassARRAY system and the iPLEX Gold Single Base Extension chemistry (Sequenom, San Diego, CA, USA). 16 Both duplicate, positive and negative control samples were included in each DNA plate to confirm the accuracy of the genotyping results. Genotyping was performed blind to phenotypic information. Furthermore, three experimental pain phenotypes were studied; cold pain intensity at 15s (NRS), heat pain intensity (NRS) and the total time the patients held their hand in cold water. Age, body mass index (BMI), state anxiety score, chronic pain and the type of surgery were used as covariates when analysing the association between the phenotypes and genotypes. These covariates were selected based on our previous findings so that the factors showing corrected p-values ≤0.001 in the linear regression analysis for at least one of the phenotypes studied here were included. 18 The 70 day surgery patients were removed from the analysis when assessing total oxycodone consumption as they did not use the PCA system.
The P-value for the primary phenotype was not corrected because only one test was performed. The P-values for the secondary phenotypes were Bonferroni corrected with the number of all tests performed (nine phenotypes). The level of statistical significance was set at a corrected empirical P<0.05.
Multiple linear regression
Data were analyzed using the R program package version 2.14. polymorphism to be able to estimate the effect of the polymorphism alone. The effect of the whole model on the studied variables i.e. the proportion of the total variance explained is presented using a multiple r-squared value.
Results
Patient characteristics
Patient characteristics grouped by the OPRM1 118A>G genotype are shown in had also axillary clearance. The effect of type of surgery on the amount of oxycodone needed for the first state of satisfactory analgesia is shown in Figure 2 .
The mean time from emergence from anesthesia to the first state of adequate analgesia was 36 min (range 0-132 min) and the mean dose required to achieve adequate analgesia was 0. 
Postoperative pain
The association results for the postoperative phenotypes are shown in Table 2 Table 2 . Mean values of the studied variables for each genotypic group and the association of OPRM1 118A>G with the primary and the secondary phenotypes.
Secondary experimental pain phenotypes
Association results are based on linear regression analysis using age, BMI, anxiety score, chronic pain and type of surgery as covariates. Additive model was used. Empirical P-values are produced by performing 10.000 permutations. * P-values for the secondary phenotypes are corrected for multiple testing using Bonferroni correction (eight phenotypes).
There was no statistically significant difference in the total oxycodone consumption during the 20 h (uncorrected P=0.58, β =0.005), even though the GG-group needed slightly more oxycodone than the AA-or AG-groups (0.265 mg kg 
Experimental pain
Data on experimental cold pain were available from 893 patients due to the unavailability of the device at the beginning of the study. No association was found between 118A>G and either cold or heat pain. Association results for experimental pain are shown in Table 2 .
Multiple linear regression models
The created multiple linear models are presented in Table 3 . The age of the patient (P=6.6x10 -08
) and the type of surgery performed (P=4.7 x 10 -09 ) were very significant factors in explaining the overall variance in the amount of oxycodone the patients requested in order to achieve the first state of adequate analgesia. The 118A>G polymorphism (P=0.0009) and anxiety (P=0.006) were also significantly associated. All these factors together explained approximately 12.6% of the variance. Based on the modelling results done excluding the polymorphism we concluded that although being a significant explaining factor, the 118A>G polymorphism alone explained less than 1% of the variance (data not shown).
When a similar modeling approach was used for total oxycodone consumption, there was no evidence for the 118A>G polymorphism to be an explaining factor (P=0.706). Table 3 . Effects of each covariate on oxycodone consumption and the proportion of the total variance explained by the whole model. Beta shows the change in oxycodone consumption corresponding to each one unit increase in the covariate. polymorphism to be of minor importance. 35 Yet several studies have associated the 118A>G polymorphism to increased opioid consumption and pain sensitivity. 7, 8, 28, 29, 31 In four studies large differences in total postoperative opioid consumption were seen. 8, 28, 29, 31 All these studies had large sample sizes consisting of Asian patients and used morphine. In Caucasian populations the effect has been smaller or non-existent. 4, 11, 21, 40 The GG genotype is much rarer in the Caucasian population 21, 26, 40 compared with the Asian population 10, 19, 31 which may explain some of the difference. In addition, many of the negative studies have had small sample sizes 4, 9, 11 or a low frequency of the G-allele. 3, 15, 21 Two previous studies have used a different approach to measure the effect of muopioid receptor genotype on postoperative pain. 5, 36 In these studies the amount of opioids given to subjects has been standardized and the focus has been on the pain score. The study published by Wu and others 36 reported significantly higher pain scores in the AG-and GG-group during the first postoperative hour compared to the AA-group. This is in agreement with our results.
When considering the association of the 118A>G polymorphism with the amount of oxycodone needed for the patient to achieve satisfactory analgesia, the estimated effect size was 0.016 mg kg -¹ per minor allele. The GG-group required on the average 30% more oxycodone compared with the AA-group even though the GGgroup had a lower frequency of axillary clearances compared with the AA-group (Table 1) . Axillary clearance was related to significantly more oxycodone consumption compared with sentinel biopsies (Figure 2 ).
There are many other factors affecting the need for analgesia as indicated in Table   3 which also shows that type of surgery, age, BMI, previous chronic pain, anxiety and the 118A>G polymorphism explain only 12.6 to 17.7% of the variation in oxycodone requirements at the first state of satisfaction and over 20 h, respectively. The effect of these other significant explaining factors has been discussed in our previous study. 18 Also, acute postoperative pain is modulated by many biological processes and hence by many different genes.
Experimental pain
The association of 118A>G polymorphism with experimental pain has not been much studied. Three studies with low numbers of subjects 7, 38, 39 have associated it with higher pain thresholds for experimental pain caused by pressure, cold or electrical stimulation. Fillingim and others 7 reported that carriers of the G-allele had lower pain thresholds for mechanical stimuli than non-carriers. Their results also suggested a gender difference as females carrying the G-allele reported higher heat pain scores whereas men reported lower pain scores compared with AA-individuals. A similar trend was reported by Lötsch and others. 24 In our study there was no association between either experimental heat or cold pain sensitivity and the 118A>G polymorphism in agreement with Huang and co-workers. 12 It is not surprising that the fairly low intensity stimulation with 48°C for 5 s did not show any association with the polymorphism. However, one would have expected an association in the cold pain test, which is very unpleasant and could activate stress-induced analgesia which is at least partly mediated by the endogenous opioid system. 20 
Study limitations
This study was performed in female patients only. Therefore, no conclusions can be made regarding males. Even though our cohort was large, the number of individuals homozygous for the minor allele (GG) was still relatively low. This affects the power of our study to detect effects specific to the homozygous carriers.
Conclusion
The mu-opioid receptor polymorphism 118A>G was associated with a significantly increased need for oxycodone in the early postoperative period but it was not associated with experimental pain sensitivity. Due to differences in allelic frequency of 118A>G the impact of this mutation is lower in the Caucasian population than in the Asian population. The higher allelic frequency of this polymorphism may render this mutation more eminent in the Asian population.
